您的购物车当前为空
L002 是一种细胞可渗透的,可逆特定性乙酰转移酶 p300(KAT3B)抑制剂,IC50为 1.98 μM。 它结合乙酰辅酶 A 口袋并竞争性抑制 FATp300 催化结构域,阻断组蛋白乙酰化和 p53 乙酰化,且抑制 STAT3 激活,有用于高血压引起的心脏肥大和纤维化的研究潜力。
L002 是一种细胞可渗透的,可逆特定性乙酰转移酶 p300(KAT3B)抑制剂,IC50为 1.98 μM。 它结合乙酰辅酶 A 口袋并竞争性抑制 FATp300 催化结构域,阻断组蛋白乙酰化和 p53 乙酰化,且抑制 STAT3 激活,有用于高血压引起的心脏肥大和纤维化的研究潜力。


为众多的药物研发团队赋能,
让新药发现更简单!
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 313 | 现货 | |
| 5 mg | ¥ 725 | 现货 | |
| 10 mg | ¥ 1,070 | 现货 | |
| 25 mg | ¥ 2,460 | 现货 | |
| 50 mg | ¥ 3,660 | 现货 | |
| 100 mg | ¥ 5,250 | 现货 | |
| 200 mg | ¥ 7,350 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 813 | 现货 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | L002, a potent, cell-permeable, reversible, and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM, directly binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain. By blocking histone acetylation, p53 acetylation, and STAT3 activation, L002 shows potential in the treatment of hypertension‐induced cardiac hypertrophy and fibrogenesis. |
| 靶点活性 | GCN5:34 µM , KAT3B:1.98 uM , PCAF:35 µM |
| 体外活性 | L002 also has weak inhibitory effects against PCAF and GCN5 (IC50s =35 and 34 μM, respectively) and is specific for p300 over a panel of deacetylases, additional acetyltransferases, and methyltransferases. |
| 体内活性 | L002 reverses hypertension‐induced cardiac hypertrophy and fibrosis by treatment of mice after inducing hypertension for two weeks significantly.It also reduces the levels of perivascular and interstitial collagen in the myocardium compared to non-treated hypertensive mice. |
| 分子量 | 321.35 |
| 分子式 | C15H15NO5S |
| CAS No. | 321695-57-2 |
| Smiles | COc1ccc(cc1)S(=O)(=O)ON=C1C=C(C)C(=O)C(C)=C1 |
| 密度 | 1.28 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 60 mg/mL (186.71 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.22 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | ||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多